Virtual Care: A New Era in Neurology

By Staff Writer

September 6, 2023

As the world grapples with an ageing population and increasing prevalence of chronic diseases, the demand for continuous home and institutional care is expected to rise significantly. This growing need, coupled with the ongoing COVID-19 pandemic, has led to a major advance in the use of virtual care tools. These tools have been instrumental in ensuring access to care and services, promoting continuity of care, and are now being integrated into care pathways for the evaluation, treatment, and follow-up of patients in specialty medicine, particularly neurology.

The Ministère de la Santé et des Services sociaux (MSSS) has initiated a national project on virtual care, mandating the Institut national d’excellence en santé et en services sociaux (INESSS) to provide a state-of-knowledge report to guide the use of virtual care in specialty medicine. This initiative aims to inform public decision-makers, medical associations, and health and social services professionals about virtual care practices in specialty medicine.

The project comprises seven reports, one of which focuses on neurology. The report presents a scoping review of the care pathways that can be supported or optimised with the use of virtual care. The review encompassed scientific and grey literature from the past five years, existing national and international guidelines, guidance and discussion papers, and health technology assessment (HTA) reports.

The findings from the review suggest that telerehabilitation is the most studied intervention across all care pathways. The review also highlights the need for additional good-quality studies to further validate the effectiveness of virtual care interventions.

The report also outlines several care pathways in neurology that have been reported as being clinically effective through the use of virtual care. These include identifying and diagnosing mild and major neurocognitive disorders via teleconsultation, improving cognitive functions through telerehabilitation via videoconferencing, and improving motor functions through physical telerehabilitation via videoconferencing among others.

Despite the promising results, the report also acknowledges the limitations of the study and the need for further research to clarify certain aspects of virtual care. Nevertheless, the findings provide valuable insights into the potential of virtual care in transforming the field of neurology and healthcare as a whole.

As the world continues to navigate through the challenges of the pandemic, the integration of virtual care in healthcare systems worldwide is more important than ever. It is hoped that with continued research and advancements in technology, virtual care will continue to improve access to healthcare and foster patient engagement in managing their illnesses. 

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.